{'52WeekChange': 5.3018575,
 'SandP52WeekChange': None,
 'address1': 'Jerusalem BioPark',
 'address2': '2nd floor Hadassah Ein Kerem Campus',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 40.98,
 'askSize': 1000,
 'averageDailyVolume10Day': 109975,
 'averageVolume': 129252,
 'averageVolume10days': 109975,
 'beta': 2.160224,
 'beta3Year': None,
 'bid': 40.63,
 'bidSize': 800,
 'bookValue': 0.61,
 'category': None,
 'circulatingSupply': None,
 'city': 'Jerusalem',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 41.82,
 'dayLow': 37.72,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 415239072,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '972 8 930 2531',
 'fiftyDayAverage': 30.298857,
 'fiftyTwoWeekHigh': 62,
 'fiftyTwoWeekLow': 5.2,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 5727407,
 'forwardEps': -0.06,
 'forwardPE': -674.8334,
 'fromCurrency': None,
 'fullTimeEmployees': 25,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.41282,
 'heldPercentInstitutions': 0.046079997,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/biondvax.com',
 'longBusinessSummary': 'BiondVax Pharmaceuticals Ltd., a clinical stage '
                        'biopharmaceutical company, focuses on developing and '
                        'commercializing immunomodulation therapies for '
                        'infectious diseases primarily in Israel. Its product '
                        'candidate is M-001, a synthetic peptide-based '
                        'protein, which is in Phase III clinical trials for '
                        'treatment of seasonal and pandemic strains of the '
                        'influenza virus. The company was founded in 2003 and '
                        'is headquartered in Jerusalem, Israel.',
 'longName': 'BiondVax Pharmaceuticals Ltd.',
 'market': 'us_market',
 'marketCap': 466469120,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_9300995',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 40,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 8 930 2529',
 'previousClose': 40.71,
 'priceHint': 2,
 'priceToBook': 66.37705,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 41.82,
 'regularMarketDayLow': 37.72,
 'regularMarketOpen': 40,
 'regularMarketPreviousClose': 40.71,
 'regularMarketPrice': 40,
 'regularMarketVolume': 118280,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 11520600,
 'sharesPercentSharesOut': 0.00090000004,
 'sharesShort': 8095,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7649,
 'shortName': 'BiondVax Pharmaceuticals Ltd.',
 'shortPercentOfFloat': None,
 'shortRatio': 0.13,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'BVXV',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.296,
 'twoHundredDayAverage': 15.909439,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'bfbba508-9a24-3c23-846c-93d8347cff9e',
 'volume': 118280,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.biondvax.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '7414002'}